TN2010000059A1 - Anticorps humains a affinite elvee pour le facteur de croisance nerveuse humain - Google Patents

Anticorps humains a affinite elvee pour le facteur de croisance nerveuse humain

Info

Publication number
TN2010000059A1
TN2010000059A1 TNP2010000059A TN2010000059A TN2010000059A1 TN 2010000059 A1 TN2010000059 A1 TN 2010000059A1 TN P2010000059 A TNP2010000059 A TN P2010000059A TN 2010000059 A TN2010000059 A TN 2010000059A TN 2010000059 A1 TN2010000059 A1 TN 2010000059A1
Authority
TN
Tunisia
Prior art keywords
pain
human
growth factor
antibody
ngf
Prior art date
Application number
TNP2010000059A
Other languages
English (en)
Inventor
Lynn Macdonald
Richard Torres
Marc R Morra
Joel H Martin
Joel C Reinhardt
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of TN2010000059A1 publication Critical patent/TN2010000059A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un anticorps humain ou fragment de liaison d'antigène d'un anticorps qui se lie spécifiquement au facteur de croissance nerveuse humain (NGF) avec un KD de 5 pM ou moins, ne présente pas de réaction croisée avec la neurotrophine-3 (NT-3) , et se lie à NGF humain avec un KD d'environ 2 à environ 10 fois plus élevée que celui avec lequel l'anticorps ou fragment se lie à NGF de rat et de souris. Les anticorps sont utiles dans le traitement de la douleur, comprenant une douleur inflammatoire, une douleur d'incision postopératoire, une douleur neurophatique, une douleur de fracture, ue douleur de fracture ostéoporotique, une névralgie postherpétique, l'arthrose, la polyarthrite rhumatoide, une douleur cancéreuse, une douleur consécutive à des brulures, une douleur articulaire goutteuse, ainsi que maladies, telles que le cancer primitif du foie, le cancer du sein, et la cirrhose du foie.
TNP2010000059A 2007-08-10 2010-02-05 Anticorps humains a affinite elvee pour le facteur de croisance nerveuse humain TN2010000059A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US96422407P 2007-08-10 2007-08-10
US99452607P 2007-09-20 2007-09-20
US6286008P 2008-01-28 2008-01-28
US7925908P 2008-07-09 2008-07-09
PCT/US2008/072561 WO2009023540A1 (fr) 2007-08-10 2008-08-08 Anticorps humains anti-facteur de croissance nerveux humain de haute affinité

Publications (1)

Publication Number Publication Date
TN2010000059A1 true TN2010000059A1 (fr) 2011-09-26

Family

ID=39951432

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2010000059A TN2010000059A1 (fr) 2007-08-10 2010-02-05 Anticorps humains a affinite elvee pour le facteur de croisance nerveuse humain

Country Status (32)

Country Link
US (3) US7988967B2 (fr)
EP (2) EP2572729A3 (fr)
JP (1) JP5632744B2 (fr)
KR (2) KR101709495B1 (fr)
CN (1) CN101827609B (fr)
AU (1) AU2008287037B2 (fr)
BR (1) BRPI0815370B8 (fr)
CA (1) CA2695997C (fr)
CO (1) CO6261383A2 (fr)
CR (1) CR11298A (fr)
CY (1) CY1116072T1 (fr)
DK (1) DK2187964T3 (fr)
DO (1) DOP2010000054A (fr)
EC (1) ECSP10010029A (fr)
ES (1) ES2517872T3 (fr)
HK (1) HK1144379A1 (fr)
HR (1) HRP20141025T1 (fr)
IL (1) IL203558A (fr)
MA (1) MA31695B1 (fr)
ME (2) ME00977B (fr)
MX (1) MX2010001395A (fr)
MY (2) MY153781A (fr)
NI (1) NI201000021A (fr)
NZ (1) NZ583200A (fr)
PL (1) PL2187964T3 (fr)
PT (1) PT2187964E (fr)
RS (1) RS53661B1 (fr)
RU (1) RU2473564C2 (fr)
SI (1) SI2187964T1 (fr)
TN (1) TN2010000059A1 (fr)
WO (1) WO2009023540A1 (fr)
ZA (1) ZA201000725B (fr)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2921578C (fr) * 2002-12-24 2017-02-14 Rinat Neuroscience Corp. Anticorps anti-ngf et procedes d'utilisation de ces anticorps
US9498530B2 (en) * 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
EP2572729A3 (fr) 2007-08-10 2013-06-05 Regeneron Pharmaceuticals, Inc. Anticorps humains anti-facteur de croissance nerveux humain de haute affinité
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
WO2009150623A1 (fr) 2008-06-13 2009-12-17 Pfizer Inc Traitement de la prostatite chronique
ES2658596T3 (es) 2008-09-19 2018-03-12 Pfizer Inc. Formulación líquida estable de anticuerpos
CN103965200B (zh) 2008-09-22 2016-06-08 阵列生物制药公司 作为trk激酶抑制剂的取代的咪唑并[1,2-b]哒嗪化合物
RS57221B2 (sr) 2008-10-22 2020-08-31 Array Biopharma Inc Jedinjenja supstituisanog pirazolo[1,5-]pirimidina kao inhibitori trk kinaze
AU2016202118B2 (en) * 2009-03-20 2017-10-26 Amgen Inc. Carrier immunoglobulins and uses thereof
AR076650A1 (es) * 2009-05-04 2011-06-29 Pangenetics 110 B V Anticuerpos contra el factor de crecimiento nervioso (ngf) con una estabilidad in vivo mejorada
WO2010146511A1 (fr) 2009-06-17 2010-12-23 Pfizer Limited Traitement d'une vessie hyperactive
DK3241435T3 (da) 2009-07-08 2021-08-23 Kymab Ltd Dyremodeller og terapeutiske molekyler
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EA201792376A3 (ru) 2009-10-23 2018-08-31 Милленниум Фармасьютикалз, Инк. Молекулы анти-gcc антитела и соответствующие композиции и способы
US20110256135A1 (en) * 2010-03-17 2011-10-20 Wolfgang Fraunhofer Anti-nerve growth factor (ngf) antibody compositions
RU2735545C2 (ru) 2010-05-20 2020-11-03 Эррэй Биофарма Инк. Макроциклические соединения в качестве ингибиторов киназы trk
JOP20190250A1 (ar) * 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
AU2011291462A1 (en) * 2010-08-19 2013-03-14 Zoetis Belgium S.A. Anti-NGF antibodies and their use
AU2015258217A1 (en) * 2010-08-19 2015-12-03 Zoetis Belgium S.A. Anti-NGF antibodies and their use
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9783601B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
CN102198272B (zh) * 2011-05-27 2013-01-02 北京中科拜克生物技术有限公司 一种促进骨折愈合的药物组合物
RS56876B1 (sr) * 2011-08-11 2018-04-30 Astellas Pharma Inc Novo antitelo protiv humanog ngf
JP5813880B2 (ja) 2011-09-19 2015-11-17 カイマブ・リミテッド ヒトへの使用に合わせて作製された抗体、可変ドメインおよび鎖
WO2013045916A1 (fr) 2011-09-26 2013-04-04 Kymab Limited Chaînes légères substituts (cls) chimères comprenant vpreb humain
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
ES2749181T3 (es) 2012-04-27 2020-03-19 Millennium Pharm Inc Moléculas de anticuerpo anti-GCC y uso de las mismas para ensayar la susceptibilidad a una terapia dirigida a GCC
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
EP2859018B1 (fr) * 2012-06-06 2021-09-22 Zoetis Services LLC Anticorps anti-ngf caninisés et procédés associés
WO2014028446A1 (fr) 2012-08-13 2014-02-20 Genentech, Inc. Anticorps anti-jagged et leurs procédés d'utilisation
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
JP6135161B2 (ja) * 2013-02-08 2017-05-31 アステラス製薬株式会社 新規抗ヒトｎｇｆ抗体
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
EP3564671B1 (fr) 2013-08-23 2021-09-29 Regeneron Pharmaceuticals, Inc. Tests de diagnostic et procédés d'évaluation de la sécurité, de l'efficacité ou du résultat d'une immunothérapie spécifique aux allergènes (sit)
NL2013554B1 (en) 2013-10-01 2016-01-08 Kymab Ltd Animal models and therapeutic molecules.
WO2015112895A2 (fr) * 2014-01-24 2015-07-30 Church William R ANTICORPS SPÉCIFIQUE DE STAPHYLOCOCCUS AUREUS, PROCÉDÉ THÉRAPEUTIQUE ET PROCÉDÉ DE DÉTECTION UTILISANT CELLES-CI<i />
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
SG11201703962XA (en) 2014-11-16 2017-06-29 Array Biopharma Inc Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
HUE050831T2 (hu) 2014-11-17 2021-01-28 Regeneron Pharma Daganatkezelési módszerek a CD3XCD20 bispecifikus antitest használatával
IL282614B2 (en) 2015-02-06 2024-02-01 Cell Idx Inc Antigen-conjugated immune reagents
CN104774265B (zh) * 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 抗人神经生长因子的中和性单克隆抗体11f1及其杂交瘤细胞株
CN104910274B (zh) * 2015-02-12 2018-05-04 北京华安科创生物技术有限公司 抗人神经生长因子的中和性单克隆抗体12c11及其杂交瘤细胞株
CN104777311B (zh) * 2015-02-12 2016-08-17 北京华安科创生物技术有限公司 抗人神经生长因子hNGF的单克隆抗体及hNGF的定量检测试剂盒
US11260124B2 (en) 2015-05-22 2022-03-01 Astellas Pharma Inc. Anti-human NGF antibody Fab fragment and methods for treating postoperative pain related to NGF
US20180236032A1 (en) * 2015-08-13 2018-08-23 Merck Patent Gmbh Combination composition comprising fgf-18 compound
RU2744852C2 (ru) 2015-10-26 2021-03-16 Локсо Онколоджи, Инк. Точечные мутации в устойчивых к ингибитору trk злокачественных опухолях и связанные с ними способы
KR102400423B1 (ko) 2016-04-04 2022-05-19 록쏘 온콜로지, 인코포레이티드 (s)-n-(5-((r)-2-(2,5-디플루오로페닐)-피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-하이드록시피롤리딘-1-카복사미드의 액체 제형
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
CN107286233B (zh) * 2016-04-13 2020-11-06 舒泰神（北京）生物制药股份有限公司 低痛神经生长因子突变体
LT3800189T (lt) 2016-05-18 2023-10-10 Loxo Oncology, Inc. (s)-n-(5-((r)-2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3- il)-3-hidroksipirolidin-1-karboksamido gavimas
WO2018017604A1 (fr) * 2016-07-18 2018-01-25 Cell Idx, Inc. Composés réactifs, compositions, kits et procédés pour dosages amplifiés
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
EA201991283A9 (ru) 2016-11-29 2019-11-27 Фармацевтическая композиция для предотвращения опиоидной зависимости
WO2018118713A1 (fr) 2016-12-22 2018-06-28 Regeneron Pharmaceuticals, Inc. Procédé de traitement d'une allergie avec des anticorps monoclonaux spécifiques pour des allergènes
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN114751982B (zh) * 2017-12-15 2023-06-23 安源医药科技（上海）有限公司 抗人ngf抗体及其制备方法和用途
CN108059676B (zh) * 2017-12-28 2020-07-31 未名生物医药有限公司 一种抗人神经生长因子scFv抗体及制备方法
BR112020017701A2 (pt) 2018-03-12 2020-12-29 Zoetis Services Llc Anticorpos anti-ngf e métodos dos mesmos
US10871485B2 (en) 2018-04-13 2020-12-22 Rarecyte, Inc. Kits for labeling of biomarkers and methods of using the same
CN108623687A (zh) 2018-04-17 2018-10-09 中山康方生物医药有限公司 神经生长因子的单克隆抗体及其编码基因和应用
JPWO2019221097A1 (ja) 2018-05-15 2021-05-27 アステラス製薬株式会社 抗ヒトｎｇｆ抗体又はその抗原結合フラグメントを有効成分とする心房細動の抑制用医薬組成物
WO2020010235A1 (fr) * 2018-07-05 2020-01-09 H. Lee Moffitt Cancer Center And Research Institute Inc. Cellules car-t qui ciblent des antigènes de cellules b
US11472870B2 (en) 2018-08-10 2022-10-18 Regeneron Pharmaceuticals, Inc. Pharmaceutical composition for safe and effective treatment of knee and/or hip pain
AU2019331024A1 (en) 2018-08-31 2021-03-18 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for CD3/C20 bispecific antibodies
JP2020117502A (ja) 2019-01-28 2020-08-06 ファイザー・インク 変形性関節症の徴候および症状を処置する方法
WO2020170103A1 (fr) 2019-02-18 2020-08-27 Pfizer Inc. Procédé de traitement de la lombalgie chronique
US11345744B2 (en) 2019-05-07 2022-05-31 William R Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
CN113924315B (zh) * 2019-06-10 2022-06-28 山东博安生物技术股份有限公司 抗β-NGF纳米抗体及其应用
US20230293636A1 (en) * 2019-12-31 2023-09-21 Peptinov Pharmaceutical composition for the prevention or treatment of post-surgical pain
CN117003868B (zh) * 2020-04-17 2024-04-16 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
CN117050175A (zh) * 2020-04-17 2023-11-14 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
US20230220057A1 (en) * 2020-05-27 2023-07-13 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing nerve growth factor and uses thereof
AU2020204105B2 (en) * 2020-06-19 2023-06-08 Ampsource Biopharma Shanghai Inc. Anti-human ngf antibodies and methods using same
US11655292B2 (en) 2020-06-23 2023-05-23 Ampsource Biopharma Shanghai Inc. Anti-human NGF antibodies and methods using same
KR20230084199A (ko) 2020-09-28 2023-06-12 메디뮨 리미티드 통증 치료를 위한 화합물 및 방법
CN114470189B (zh) * 2020-11-12 2024-01-16 达石药业(广东)有限公司 Ngf抗体在cipn性疼痛中的应用
US20240117072A1 (en) * 2020-12-18 2024-04-11 Bioardis, Llc Fap binding molecules and uses thereof
WO2022195504A1 (fr) 2021-03-19 2022-09-22 Pfizer Inc. Méthode de traitement de la douleur due à l'arthrose avec un anticorps anti-ngf
WO2023092052A1 (fr) 2021-11-19 2023-05-25 Regeneron Pharmaceuticals, Inc. Méthodes et compositions pour réduire la douleur centralisée
WO2023111157A1 (fr) 2021-12-16 2023-06-22 Intervet International B.V. Anticorps caninisés et felinisés dirigés contre ngf humain
CN114397453B (zh) * 2022-03-25 2022-06-07 江苏美克医学技术有限公司 新型冠状病毒突变株的检测试剂盒及其应用
WO2023212586A1 (fr) 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Procédés de sélection de patients pour le traitement avec un antagoniste du ngf

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US514294A (en) * 1894-02-06 Governor
US5147294A (en) 1990-10-01 1992-09-15 Trustees Of Boston University Therapeutic method for reducing chronic pain in a living subject
AU675409B2 (en) * 1991-07-10 1997-02-06 Regeneron Pharmaceuticals, Inc. Methods of treatment of motor neuron diseases using members of the BDNF/NT-3/NGF family of molecules
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
IT1306704B1 (it) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
US6548062B2 (en) * 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
AU2004297218B2 (en) * 2000-09-07 2012-03-01 Amgen, Inc. Human anti-Pseudomonas-aeruginosa antibodies derived from transgenic Xenomouse
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AUPR256601A0 (en) * 2001-01-17 2001-02-08 Silverbrook Research Pty. Ltd. An apparatus (AP29)
KR20040049829A (ko) * 2001-05-30 2004-06-12 제넨테크, 인크. 다양한 질환의 치료에 유용한 항-엔지에프 항체
US7202343B2 (en) * 2002-08-19 2007-04-10 Abgenix, Inc. Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof
DE60335957D1 (de) 2002-10-08 2011-03-17 Rinat Neuroscience Corp Verfahren zur behandlung von postoperativen schmerzen durch verabreichung eines antikörpers gegen nervenwachstumsfaktor und diesen enthaltende zusammensetzungen
UA80447C2 (en) * 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US7255860B2 (en) * 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
CA2921578C (fr) * 2002-12-24 2017-02-14 Rinat Neuroscience Corp. Anticorps anti-ngf et procedes d'utilisation de ces anticorps
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
EP1594441B1 (fr) * 2003-02-19 2010-12-15 Rinat Neuroscience Corp. Methode de traitement de la douleur consistant a administrer un antagoniste du facteur de croissance neuronale ainsi que des medicaments anti-inflammatoires non steroidiens (nsaid) et composition les contenant
DK1648509T3 (da) * 2003-07-15 2013-01-07 Amgen Inc Humane anti-NGF-neutraliserende antistoffer som selektive NGF-pathway-inhibitorer
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
KR20060135060A (ko) * 2004-04-07 2006-12-28 리나트 뉴로사이언스 코퍼레이션 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
EP1740946B1 (fr) 2004-04-20 2013-11-06 Genmab A/S Anticorps monoclonaux humains diriges contre cd20
JP5096167B2 (ja) * 2005-01-24 2012-12-12 メドイミューン リミテッド Ｎｇｆに対する特異的結合メンバー
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
US7872102B2 (en) * 2005-08-25 2011-01-18 Eli Lilly And Company Anti-IL-23 antibodies
US9789161B2 (en) * 2006-04-28 2017-10-17 Warsaw Orthopedic, Inc. Methods for treating back or neck pain caused by NGF using a therapeutic agent consisting of ReN-1820, ALE-0540 and capsaicin
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
EP2572729A3 (fr) 2007-08-10 2013-06-05 Regeneron Pharmaceuticals, Inc. Anticorps humains anti-facteur de croissance nerveux humain de haute affinité
AR076650A1 (es) 2009-05-04 2011-06-29 Pangenetics 110 B V Anticuerpos contra el factor de crecimiento nervioso (ngf) con una estabilidad in vivo mejorada

Also Published As

Publication number Publication date
AU2008287037A1 (en) 2009-02-19
ZA201000725B (en) 2011-06-29
WO2009023540A1 (fr) 2009-02-19
KR101709495B1 (ko) 2017-02-23
KR20100058537A (ko) 2010-06-03
ME02239B (fr) 2015-04-30
BRPI0815370B8 (pt) 2021-05-25
BRPI0815370B1 (pt) 2020-10-20
CN101827609A (zh) 2010-09-08
CO6261383A2 (es) 2011-03-22
CA2695997C (fr) 2016-11-22
RS53661B1 (en) 2015-04-30
IL203558A (en) 2014-03-31
KR20150125735A (ko) 2015-11-09
NZ583200A (en) 2012-03-30
CY1116072T1 (el) 2017-02-08
MY161564A (en) 2017-04-28
ECSP10010029A (es) 2010-04-30
MX2010001395A (es) 2010-03-10
JP2010535509A (ja) 2010-11-25
ME00977B (me) 2012-06-20
RU2473564C2 (ru) 2013-01-27
AU2008287037B2 (en) 2013-10-10
CR11298A (es) 2010-03-23
US20110256587A1 (en) 2011-10-20
EP2187964A1 (fr) 2010-05-26
BRPI0815370A2 (pt) 2015-02-10
US7988967B2 (en) 2011-08-02
US8613927B2 (en) 2013-12-24
RU2010108525A (ru) 2011-09-20
CN101827609B (zh) 2014-03-12
SI2187964T1 (sl) 2015-01-30
US20120164688A1 (en) 2012-06-28
US20090041717A1 (en) 2009-02-12
US8148107B2 (en) 2012-04-03
KR101709488B1 (ko) 2017-02-24
DK2187964T3 (en) 2015-01-12
EP2572729A3 (fr) 2013-06-05
PT2187964E (pt) 2015-01-14
EP2187964B1 (fr) 2014-10-08
HRP20141025T1 (hr) 2015-01-02
DOP2010000054A (es) 2010-03-15
PL2187964T3 (pl) 2015-03-31
HK1144379A1 (en) 2011-02-18
NI201000021A (es) 2010-07-27
CA2695997A1 (fr) 2009-02-19
ES2517872T3 (es) 2014-11-04
MY153781A (en) 2015-03-13
JP5632744B2 (ja) 2014-11-26
MA31695B1 (fr) 2010-09-01
EP2572729A2 (fr) 2013-03-27

Similar Documents

Publication Publication Date Title
TN2010000059A1 (fr) Anticorps humains a affinite elvee pour le facteur de croisance nerveuse humain
MA35345B1 (fr) Proteines de liaisons a un antigene ayant une liaison accrue a fcrn
MA45125B1 (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA32577B1 (fr) Anticorps neutralisants le virus de l&#39;influenza a et leurs utilisations
MA28982B1 (fr) Anticorps antagonistes de il-17
MA42622B1 (fr) Agents de liaison à tigit et leurs utilisations
EA030259B8 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
SG151292A1 (en) Immunoglobulins
DE602005021072D1 (de) Adzyme und deren verwendungen
MA30337B1 (fr) Anticorps
WO2004019878A3 (fr) Adzymes et leurs utilisations
AU2018272852A8 (en) Antibodies comprising modified heavy constant regions
BRPI0809042A8 (pt) Proteína de ligação a cd154 isolada, seu uso, e composição
MA31886B1 (fr) Anticorps anti-hepcidine et utilisations de ceux-ci
WO2004066932A3 (fr) Composition permettant de traiter des maladies dues a la demyelinisation et a la paralysie par administration d&#39;agents de remyelinisation
AR072897A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
BRPI0410338A (pt) composição farmacêutica compreendendo um constructo de anticorpo biespecìfico para epcam, processo para sua produção, uso de um constructo biespecìfico, kit contendo o mesmo e método para a prevenção, tratamento ou alìvio de uma doença tumoral
EA200600037A1 (ru) Композиции и способы увеличения минерализации костей
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d&#39;un double récepteur et leurs utilisations
ATE493148T1 (de) Antikörper zur hemmung der blutgerinnung und anwendungsverfahren dafür
BR112012016309A2 (pt) &#34;porção, composição farmacêutica, uso de uma quantidade eficaz da porção, método para identificar uma porção que se liga a um domínio semelhante a ig de um receptor do fator de crescimento endotelial vascular (receptor de vegf), e, anticorpo isolado ou uma porção de ligação de antígeno deste&#34;.
MA37670B1 (fr) Anticorps anti-transglutaminase 2
WO2008008224A3 (fr) Compositions à base de récepteurs de goût acide, et procédés correspondants
Santoriello et al. Segmental NELL-1 Membranous Nephropathy Complicating Tiopronin Therapy
WO2008118324A3 (fr) Composition et procédé de traitement du cancer avec un anticorps anti-uroplakine ib